Supported by educational grants from Bayer & Exelixis, Inc.
TITLE - Personalized Care in Advanced Hepatocellular Carcinoma: Novel and Emerging Treatment Strategies
TARGET AUDIENCE - Target audiences for this program are Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses
LEARNING OBJECTIVES - After completing the program, Specialty Pharmacists, Pharmacists, Clinical Pharmacists, Specialty Pharmacy executives, Pharmacy Directors, Chief Pharmacy Officers, Oncology Pharmacists, Oncology Nurses, and Nurses
- Identify prognostic factors that can inform personalized treatment plans for patients with hepatocellular carcinoma (HCC)
- Recognize which HCC patients are not candidates for curative therapy
- Discuss therapeutic options available for patients with unresectable HCC and their mechanisms of action, efficacy, safety and tolerability
- Describe clinical data for novel and emerging therapeutic approaches in HCC, including both monotherapy and combination therapies
- Discuss important factors to educate and counsel patients on regarding the impact of HCC and its treatment
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Faculty Disclosure: Chung-Shien Lee, PharmD, BCPS, BCOP, has no relevant conflicts of interest to disclose. He does not intend to discuss non-FDA approved drugs or investigational use of any product/device.
Pharmacist continuing education credit
Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test (score of 70% or higher). Participants will have 3 opportunities to pass the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Knowledge Based Activity
Course release date 2/06/2020
Course expires 2/06/2023
Nursing continuing education credit
Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Course release date: 3/13/2020
Course expires: 3/13/2022
|Activity Number||Credit Amount||Accreditation Period|
|0535-0000-20-001-H01-P||0.15 CEUs||February 06, 2020 - February 06, 2023|
|0535-0000-20-001-H01-N||1.5 hours of CNE||March 13, 2020 - March 13, 2022|